Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results

Keros Therapeutics (NASDAQ:KROS) announced its quarterly earnings data on Wednesday. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.37), FiscalAI reports. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%. The firm had revenue of $0.39 million during the quarter, compared to analyst estimates of $3.66 million. During the same period in the prior year, the firm posted ($1.14) earnings per share. The business’s quarterly revenue was down 87.2% compared to the same quarter last year.

Keros Therapeutics Stock Up 2.8%

NASDAQ:KROS opened at $13.77 on Thursday. Keros Therapeutics has a 52-week low of $9.12 and a 52-week high of $22.55. The stock has a fifty day simple moving average of $17.81 and a 200-day simple moving average of $17.10. The company has a market capitalization of $419.57 million, a PE ratio of 8.94 and a beta of 0.87.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Zacks Research lowered Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Oppenheimer reaffirmed an “outperform” rating and set a $27.00 price objective (up from $23.00) on shares of Keros Therapeutics in a report on Wednesday, November 12th. Wells Fargo & Company reduced their target price on Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating for the company in a report on Tuesday, November 11th. TD Cowen upgraded shares of Keros Therapeutics to a “hold” rating in a research report on Friday, December 19th. Finally, Bank of America increased their price target on shares of Keros Therapeutics from $18.00 to $19.00 and gave the company a “neutral” rating in a report on Friday, November 28th. Five analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $22.29.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its holdings in shares of Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Keros Therapeutics during the 4th quarter worth approximately $212,000. New York State Common Retirement Fund lifted its stake in Keros Therapeutics by 264.1% in the 2nd quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock valued at $142,000 after buying an additional 7,700 shares in the last quarter. Sherbrooke Park Advisers LLC acquired a new stake in Keros Therapeutics during the 3rd quarter valued at $176,000. Finally, Virtus Investment Advisers LLC grew its holdings in Keros Therapeutics by 48.2% during the 4th quarter. Virtus Investment Advisers LLC now owns 12,367 shares of the company’s stock valued at $252,000 after buying an additional 4,025 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.